Sartorius Stedim Biotech Connect Upstream bioprocessing platform

Sartorius Stedim Biotech (SSB) has developed an innovative and fully integrated technology platform to meet the requirements of today’s upstream bioprocessing. Connect Upstream combines a high-performing expression system with equipment and process control for the rapid development and scale-up of robust, high-titre commercial manufacturing processes. The company claims that biopharmaceutical manufacturers will be able to reach the clinic in 14 months by leveraging the platform.

The royalty-free CHO expression platform of SSB subsidiary Cellca delivers the titres required to meet companies’ cost-of-goods objectives. Cellca can establish a research cell bank for its clients within just four months. The automated ambr15 micro bioreactor system is capable of controlling 24 or 48 micro bioreactor experiments.

The system accelerates clone selection and scales up readily to BIOSTAT STR single-use bioreactors, which biomanufacturers have successfully implemented at pilot and GMP production scales. To reduce early-stage development timelines still further, Sartorius Stedim Biotech has integrated more than 100 off-the-shelf and prequalified assays from BioOutsource into its platform, allowing the rapid testing and analysis of biosimilar products.